Literature DB >> 16153159

Distal ERBB2 promoter fragment displays specific transcriptional and nuclear binding activities in ERBB2 overexpressing breast cancer cells.

Laurence Delacroix1, Dominique Begon, Guillaume Chatel, Pascale Jackers, Rosita Winkler.   

Abstract

Overexpression of the ERBB2 gene occurs in 30% of human breast cancers and is correlated with poor prognosis. The deregulation is the consequence of an increased transcription level and gene amplification. Several laboratories, including our own, have identified, in the proximal promoter, enhancers implicated in the gene overexpression. However, our previous studies of a 6-kb ERBB2 promoter fragment revealed the presence of repressing fragments, which were able to overcome the effect of the proximal enhancers. These repressing elements were functional in all cell lines, regardless of their endogenous ERBB2 expression level. Here, we show that a distal ERBB2 promoter region restores high transcription rates specifically in ERBB2 overexpressing breast cancer cells. This distal promoter region thus contains enhancers essential for the overexpression of the gene. By EMSA, performed with nuclear extract of cells overexpressing (BT-474) or not (MDA-MB-231) the ERBB2 gene, we show that at least two sequences of the distal promoter region are bound exclusively by BT-474 extract. Further experiments reveal that AP-2 transcription factors contribute to this differential binding activity, by binding recognition sequences located 4500 bp and 4000 bp upstream of the transcription start site. These sites are occupied by AP2 in vivo, as demonstrated by ChIP assay. Inactivation of AP-2 proteins in ERBB2 overexpressing cells reduces the distal promoter activity up to 70%, indicating the AP-2 factors are implicated in the strong distal enhancing effect. Moreover, we identified a 54-bp fragment that is bound specifically by BT-474 nuclear extract. Further experiments did not lead to the identification of the protein responsible for this binding. Our results thus highlight the importance of ERBB2 distal promoter region and further implicate AP-2 in ERBB2 overexpression in breast cancer cells.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16153159     DOI: 10.1089/dna.2005.24.582

Source DB:  PubMed          Journal:  DNA Cell Biol        ISSN: 1044-5498            Impact factor:   3.311


  17 in total

1.  PPARγ and NF-κB regulate the gene promoter activity of their shared repressor, TNIP1.

Authors:  Igor Gurevich; Carmen Zhang; Priscilla C Encarnacao; Charles P Struzynski; Sarah E Livings; Brian J Aneskievich
Journal:  Biochim Biophys Acta       Date:  2011-10-07

2.  A TFAP2C Gene Signature Is Predictive of Outcome in HER2-Positive Breast Cancer.

Authors:  Vincent T Wu; Boris Kiriazov; Kelsey E Koch; Vivian W Gu; Anna C Beck; Nicholas Borcherding; Tiandao Li; Peter Addo; Zachary J Wehrspan; Weizhou Zhang; Terry A Braun; Bartley J Brown; Vimla Band; Hamid Band; Mikhail V Kulak; Ronald J Weigel
Journal:  Mol Cancer Res       Date:  2019-10-16       Impact factor: 5.852

3.  Distinct regulatory mechanism of immunoglobulin gene transcription in epithelial cancer cells.

Authors:  Xiaohui Zhu; Lina Wu; Li Zhang; Peng Hao; Shuai Zhang; Jing Huang; Jie Zheng; Yinan Liu; Wenjun Li; Yingmei Zhang; Chunyan Zhou; Youhui Zhang; C Cameron Yin; Xiaoyan Qiu
Journal:  Cell Mol Immunol       Date:  2010-05-17       Impact factor: 11.530

4.  Identification of primary gene targets of TFAP2C in hormone responsive breast carcinoma cells.

Authors:  George W Woodfield; Yizhen Chen; Thomas B Bair; Frederick E Domann; Ronald J Weigel
Journal:  Genes Chromosomes Cancer       Date:  2010-10       Impact factor: 5.006

5.  The role of Tcfap2c in tumorigenesis and cancer growth in an activated Neu model of mammary carcinogenesis.

Authors:  J M Park; T Wu; A R Cyr; G W Woodfield; J P De Andrade; P M Spanheimer; T Li; S L Sugg; G Lal; F E Domann; W Zhang; R J Weigel
Journal:  Oncogene       Date:  2015-03-16       Impact factor: 9.867

6.  Stat3 regulates ErbB-2 expression and co-opts ErbB-2 nuclear function to induce miR-21 expression, PDCD4 downregulation and breast cancer metastasis.

Authors:  L Venturutti; L V Romero; A J Urtreger; M F Chervo; R I Cordo Russo; M F Mercogliano; G Inurrigarro; M G Pereyra; C J Proietti; F Izzo; M C Díaz Flaqué; V Sundblad; J C Roa; P Guzmán; E D Bal de Kier Joffé; E H Charreau; R Schillaci; P V Elizalde
Journal:  Oncogene       Date:  2015-07-27       Impact factor: 9.867

7.  A genome-inspired, reverse selection approach to aptamer discovery.

Authors:  Christina M Albanese; Suttipong Suttapitugsakul; Shruthi Perati; Linda B McGown
Journal:  Talanta       Date:  2017-09-01       Impact factor: 6.057

8.  Sumoylation pathway is required to maintain the basal breast cancer subtype.

Authors:  Maria V Bogachek; Yizhen Chen; Mikhail V Kulak; George W Woodfield; Anthony R Cyr; Jung M Park; Philip M Spanheimer; Yingyue Li; Tiandao Li; Ronald J Weigel
Journal:  Cancer Cell       Date:  2014-05-15       Impact factor: 31.743

9.  Ku proteins interact with activator protein-2 transcription factors and contribute to ERBB2 overexpression in breast cancer cell lines.

Authors:  Grégory Nolens; Jean-Christophe Pignon; Benjamin Koopmansch; Benaïssa Elmoualij; Willy Zorzi; Edwin De Pauw; Rosita Winkler
Journal:  Breast Cancer Res       Date:  2009-11-11       Impact factor: 6.466

10.  Identification of PADI2 as a potential breast cancer biomarker and therapeutic target.

Authors:  John L McElwee; Sunish Mohanan; Obi L Griffith; Heike C Breuer; Lynne J Anguish; Brian D Cherrington; Ashley M Palmer; Louise R Howe; Venkataraman Subramanian; Corey P Causey; Paul R Thompson; Joe W Gray; Scott A Coonrod
Journal:  BMC Cancer       Date:  2012-10-30       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.